Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Arteris, Inc. (AIP) – Form 144 insider sale notice
Senior insider Nicholas Hawkins filed a Form 144 indicating an intent to sell 5,638 common shares of Arteris on 26-27 June 2025 through Morgan Stanley Smith Barney. Based on the stated price, the shares carry an aggregate market value of $54,012.04. With 41,977,728 shares outstanding, the proposed sale represents roughly 0.013 % of the company’s equity, a de-minimis portion of the float.
The shares were originally acquired on 19 December 2019 via the cash exercise of stock options. The filing states the sale will occur under a Rule 10b5-1 trading plan, signalling the trades were pre-arranged and not based on undisclosed information.
Recent insider activity: The same insider has executed several sales over the past three months, amounting to 37,772 shares for approximately $302,155 in gross proceeds. Transaction sizes ranged from 438 to 11,000 shares per trade.
While insider sales do not automatically imply negative prospects, some investors monitor the frequency of such transactions. The currently disclosed sale remains immaterial relative to Arteris’ share count and does not on its own alter the investment thesis.
Arteris (NASDAQ:AIP) filed a Form 4 showing that VP & CFO Nicholas B. Hawkins sold a total of 11,276 common shares on 25-26 Jun 2025 under a pre-arranged Rule 10b5-1 plan.
- Sales volume: 5,638 shares at $9.50 and 5,638 at $9.75, raising roughly $108k.
- Ownership impact: holdings fell from 161,937 to 150,661 shares, a 7% reduction.
- Plan history: the 10b5-1 plan was adopted 20 May 2024; no derivative transactions were reported.
The transaction is modest in dollar terms but material in percentage for a C-suite executive, potentially influencing short-term sentiment.
Form 144 Notice of Proposed Sale filed by Arteris details insider trading activity by Nicholas Hawkins. The filing indicates a proposed sale of 11,276 shares of common stock with an aggregate market value of $101,709.52 through Morgan Stanley Smith Barney LLC, planned for execution on June 25, 2025 on NASDAQ.
Key transaction details:
- Original acquisition: 11,276 shares via stock options on December 19, 2019
- Current outstanding shares: 41,977,728
- Recent trading history: Hawkins executed multiple sales in past 3 months totaling 26,496 shares for approximately $193,623
- Most transactions were conducted under a 10b5-1 trading plan
This Form 144 represents a standard insider sale notification, with the seller affirming no knowledge of undisclosed material adverse information regarding Arteris's operations.